Stay updated on CP-690,550 Doses vs. Placebo in Arthritis Clinical Trial
Sign up to get notified when there's something new on the CP-690,550 Doses vs. Placebo in Arthritis Clinical Trial page.

Latest updates to the CP-690,550 Doses vs. Placebo in Arthritis Clinical Trial page
- CheckyesterdayChange DetectedThe page has removed a citation regarding the efficacy and safety of tofacitinib, including an erratum reference.SummaryDifference0.1%
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a Phase 3 study on CP-690,550 for rheumatoid arthritis, while a new revision number has been added.SummaryDifference4%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
Stay in the know with updates to CP-690,550 Doses vs. Placebo in Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CP-690,550 Doses vs. Placebo in Arthritis Clinical Trial page.